Industry Leading Test Laboratory, BioScience Laboratories, Inc. Concludes Phase 1 Safety Evaluations in 12 Weeks, Exceeds Market Value, and Timeline, Again

Bozeman, MT (PRWEB) May 22, 2013

BioScience Laboratories clinical laboratory has again exceeded market standards for Phase 1 Dermatological Safety Studies for an IND submission. Twenty-two years of experience has refined our processes and set our practice apart. Phase 1 Dermatological Safety Studies represent a critical transition into the human model for every IND and ANDA submission. Sponsors require quality safety data in a reasonable amount of time, with a reasonable fee. Shorter turn-around times increase project progress and allow efficacy trials to initiate sooner.